14-3-3sigma protein (stratifin)

Stains
14-3-3sigma protein (stratifin)

Author: Nat Pernick, M.D. (see Authors page)

Revised: 3 November 2015, last major update July 2013

Copyright: (c) 2003-2015, PathologyOutlines.com, Inc.

PubMed Search: (14-3-3sigma [title]) OR 14-3-3 sigma[title]

Table of Contents

Cite this page: 14-3-3sigma protein (stratifin). PathologyOutlines.com website. http://www.pathologyoutlines.com/topic/stains1433sigma.html. Accessed July 12th, 2017.

Definition / general

Member of highly conserved family of 14-3-3 acidic proteins present in all eukaryotic organisms (Wikipedia)
Transcriptionally activated by p53 after DNA damage; facilitates DNA repair during G2 arrest (Oncogene 2006;25:4559)
Considered a tumor suppressor with reduced expression in some cancers (inactivated by promoter hypermethylation, Mod Pathol 2005;18:340, Am J Clin Pathol 2010;133:232), and increased expression causes resistance to some antitumor agents (Am J Transl Res 2009;1:326)

Clinical features

Down regulation is associated with poor outcome in intrahepatic cholangiocarcinoma (Hum Pathol 2007;38:1014)
Increased expression associated with poor prognosis in breast cancer (Cancer Biomark 2009;5:215, also poorer response to neoadjuvant chemotherapy, Breast Cancer Res Treat 2012;134:229), nasopharyngeal carcinoma-undifferentiated (Oncol Rep 2010;24:949), pancreatic cancer (BMC Cancer 2010;10:598), stomach cancer (BMC Cancer 2011;11:397)

Diagrams / tables

Function in DNA damage response

Uses by pathologists

None at this time

Microscopic (histologic) images

Images hosted on other servers:

Breast: normal to invasive carcinoma

Cervix: normal

Cervix: LSIL

Cervix: HSIL

Cervix: invasive squamous cell carcinoma

Lung: non-small cell cancer

Lung: adenocarcinoma

Oral cavity: normal to carcinoma

Oral cancer (fig 1B)

Stomach: normal and carcinoma

Images hosted on Nature.com:

GU and Gyn: normal to malignant

Positive staining - normal

Breast and prostate periductal and periglandular cells, urothelium, uterus (strong in squamous epithelium, weak in endometrial and endocervical glands)
Myoepithelial marker in breast (Am J Surg Pathol 2005;29:347)

Positive staining - disease

Bladder urothelial carcinoma (98%), breast carcinoma (23%), cervical squamous cell carcinoma (67%), endometrial adenocarcinoma (57%), ovarian carcinoma (33%), prostatic adenocarcinoma (55%), renal carcinoma (12%), testicular tumors (27%)

Negative stains

Kidney (sporadic expression in tubules), germinal cells of ovary and testis